

# Ruben Queiro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6423968/publications.pdf>

Version: 2024-02-01

158  
papers

3,081  
citations

159573

30  
h-index

214788

47  
g-index

174  
all docs

174  
docs citations

174  
times ranked

2930  
citing authors

#	ARTICLE	IF	CITATIONS
1	A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 68-70.	0.9	125
2	Power Doppler Ultrasonography Assessment of Entheses in Spondyloarthropathies: Response to Therapy of Enteseal Abnormalities. <i>Journal of Rheumatology</i> , 2010, 37, 2110-2117.	2.0	125
3	Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2013, 169, 783-793.	1.5	124
4	Age at disease onset: a key factor for understanding psoriatic disease. <i>Rheumatology</i> , 2014, 53, 1178-1185.	1.9	103
5	Subclinical Sacroiliitis in Inflammatory Bowel Disease: A Clinical and Follow-up Study. <i>Clinical Rheumatology</i> , 2000, 19, 445-449.	2.2	86
6	Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes. <i>Human Molecular Genetics</i> , 2012, 21, 4549-4557.	2.9	79
7	Clinical features and predictive factors in psoriatic arthritis-related uveitis. <i>Seminars in Arthritis and Rheumatism</i> , 2002, 31, 264-270.	3.4	78
8	Psoriatic spondyloarthropathy: A comparative study between HLA-B27 positive and HLA-B27 negative disease. <i>Seminars in Arthritis and Rheumatism</i> , 2002, 31, 413-418.	3.4	78
9	Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus. <i>Journal of Dermatological Science</i> , 2014, 75, 167-172.	1.9	73
10	Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1759-1766.	3.4	73
11	Clinically Asymptomatic Axial Disease in Psoriatic Spondyloarthropathy. A Retrospective Study. <i>Clinical Rheumatology</i> , 2002, 21, 10-13.	2.2	70
12	Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. <i>Arthritis Research and Therapy</i> , 2017, 19, 72.	3.5	64
13	An unexpectedly high frequency of <i>MEFV</i> mutations in patients with anti-citrullinated protein antibody-negative palindromic rheumatism. <i>Arthritis and Rheumatism</i> , 2007, 56, 2784-2788.	6.7	63
14	HLA-B27 and psoriatic disease: a modern view of an old relationship. <i>Rheumatology</i> , 2016, 55, 221-229.	1.9	56
15	Clinical Differences between Men and Women with Psoriatic Arthritis: Relevance of the Analysis of Genes and Polymorphisms in the Major Histocompatibility Complex Region and of the Age at Onset of Psoriasis. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-7.	3.3	52
16	HLA-C locus alleles may modulate the clinical expression of psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2006, 8, R185.	3.5	49
17	Comprehensive Treatment of Dactylitis in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2295-2300.	2.0	45
18	Haematogenous Vertebral Osteomyelitis in the Elderly. <i>Clinical Rheumatology</i> , 2000, 19, 344-347.	2.2	44

#	ARTICLE	IF	CITATIONS
19	Obesity in psoriatic arthritis. <i>Medicine (United States)</i> , 2019, 98, e16400.	1.0	44
20	Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 355-364.	0.9	44
21	Comparative analysis of psoriatic spondyloarthropathy between men and women. <i>Rheumatology International</i> , 2001, 21, 66-68.	3.0	43
22	The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B*27 Status?. <i>Arthritis Care and Research</i> , 2021, 73, 856-860.	3.4	43
23	HLA antigens may influence the age of onset of psoriasis and psoriatic arthritis. <i>Journal of Rheumatology</i> , 2003, 30, 505-7.	2.0	41
24	Association between single nucleotide polymorphisms IL17RA rs4819554 and IL17E rs79877597 and Psoriasis in a Spanish cohort.. <i>Journal of Dermatological Science</i> , 2015, 80, 111-115.	1.9	39
25	High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). <i>Rheumatology</i> , 2011, 50, 1828-1837.	1.9	38
26	MHC class I chain-related gene B (MICB) is associated with rheumatoid arthritis susceptibility. <i>Rheumatology</i> , 2007, 46, 426-430.	1.9	35
27	RS3PE syndrome: a clinical and immunogenetical study. <i>Rheumatology International</i> , 2004, 24, 103-105.	3.0	33
28	Modelos de atención multidisciplinar en pacientes con artritis psoriásica en España. <i>Reumatología Clínica</i> , 2017, 13, 85-90.	0.5	33
29	Recomendaciones de la Sociedad Española de Reumatología sobre el tratamiento y uso de terapias sistémicas biológicas y no biológicas en artritis psoriásica. <i>Reumatología Clínica</i> , 2018, 14, 254-268.	0.5	32
30	The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients. <i>Archives of Dermatological Research</i> , 2015, 307, 405-412.	1.9	30
31	SNP rs11652075 in the <i>CARD14</i> Gene as a Risk Factor for Psoriasis (PSORS2) in a Spanish Cohort. <i>DNA and Cell Biology</i> , 2013, 32, 601-604.	1.9	29
32	The effect of HLA-DR antigens on the susceptibility to, and clinical expression of psoriatic arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2004, 33, 318-322.	1.1	27
33	Clinical expression, but not disease outcome, may vary according to age at disease onset in psoriatic spondylitis. <i>Joint Bone Spine</i> , 2008, 75, 544-547.	1.6	27
34	Common and rare <i>CARD14</i> gene variants affect the antitumour necrosis factor response among patients with psoriasis. <i>British Journal of Dermatology</i> , 2016, 175, 134-141.	1.5	27
35	Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study. <i>Frontiers in Medicine</i> , 2021, 8, 679009.	2.6	27
36	Mutation analysis of the LCE3B/LCE3C genes in Psoriasis. <i>BMC Medical Genetics</i> , 2010, 11, 45.	2.1	24

#	ARTICLE	IF	CITATIONS
37	Performance of the ASAS Health Index for the Evaluation of Spondyloarthritis in Daily Practice. <i>Journal of Rheumatology</i> , 2020, 47, 1483-1489.	2.0	24
38	Association of intermittent hydrarthrosis with MEFV gene mutations. <i>Arthritis and Rheumatism</i> , 2006, 54, 2334-2335.	6.7	23
39	Enthesal ultrasound abnormalities in patients with SAPHO syndrome. <i>Clinical Rheumatology</i> , 2012, 31, 913-919.	2.2	23
40	Diferente expresi3n cl3nica de los pacientes con espondilitis anquilosante seg3n el sexo en funci3n del tiempo de evoluci3n. Datos de REGISPONSER. <i>Reumatolog3a Cl3nica</i> , 2013, 9, 221-225.	0.5	23
41	Age at disease onset may help to further characterize the disease phenotype in psoriatic arthritis. <i>Joint Bone Spine</i> , 2016, 83, 533-537.	1.6	23
42	Consensus Statement of the Spanish Society of Rheumatology on Risk Management of Biologic Therapy in Rheumatic Patients. <i>Reumatolog3a Cl3nica (English Edition)</i> , 2011, 7, 284-298.	0.3	21
43	Patients with psoriatic arthritis may show differences in their clinical and genetic profiles depending on their age at psoriasis onset. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 476-80.	0.8	21
44	The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 313-316.	1.5	20
45	CDKAL1 gene variants affect the anti-TNF response among Psoriasis patients. <i>International Immunopharmacology</i> , 2015, 29, 947-949.	3.8	19
46	Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 710-715.	2.0	19
47	Higher prevalence of psoriatic arthritis in the adult population in Spain? A population-based cross-sectional study. <i>PLoS ONE</i> , 2020, 15, e0234556.	2.5	19
48	The Impact of Comorbidity on Patient-Reported Outcomes in Psoriatic Arthritis: A Systematic Literature Review. <i>Rheumatology and Therapy</i> , 2020, 7, 237-257.	2.3	19
49	A deletion at ADAMTS9-MAGI1 locus is associated with psoriatic arthritis risk. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1875-1881.	0.9	18
50	Activating killer immunoglobulin-like receptors genes are associated with increased susceptibility to ankylosing spondylitis. <i>Clinical and Experimental Immunology</i> , 2015, 180, 201-206.	2.6	18
51	Patient-reported outcomes in European spondyloarthritis patients: a systematic review of the literature. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 733-747.	1.8	18
52	Psoriatic Arthropathy after BCG Immunotherapy for Bladder Carcinoma. <i>Rheumatology</i> , 1995, 34, 1097-1097.	1.9	17
53	Standards of care for patients with spondyloarthritis. <i>Rheumatology International</i> , 2014, 34, 165-170.	3.0	17
54	Prevalence and Predictors of Cervical Involvement in Psoriatic Spondyloarthropathy. <i>Journal of Clinical Rheumatology</i> , 2002, 8, 23-29.	0.9	16

#	ARTICLE	IF	CITATIONS
55	Successful Treatment with Low-Dose Weekly Methotrexate in a Case of Undifferentiated Spondyloarthritis coexisting with Cutaneous Polyarteritis Nodosa. <i>Clinical Rheumatology</i> , 2002, 21, 304-305.	2.2	16
56	Successful therapy with low-dose colchicine in intermittent hydrarthrosis. <i>British Journal of Rheumatology</i> , 2003, 42, 391-392.	2.3	16
57	Prevalence and type II diabetes-associated factors in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 1059-1064.	2.2	16
58	Resequencing of the IL12B gene in psoriasis patients with the rs6887695/rs3212227 risk genotypes. <i>Cytokine</i> , 2012, 60, 27-29.	3.2	15
59	Dropped Head Syndrome in a Patient With Scleromyositis. <i>Journal of Clinical Rheumatology</i> , 2013, 19, 32-34.	0.9	15
60	NFKBIZ and CW6 in Adalimumab Response Among Psoriasis Patients: Genetic Association and Alternative Transcript Analysis. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 627-633.	3.8	15
61	Construct validity of the ASAS health index in psoriatic arthritis: a cross-sectional analysis. <i>Rheumatology</i> , 2021, 60, 1465-1473.	1.9	15
62	A Single Nucleotide Polymorphism in the IL17ra Promoter Is Associated with Functional Severity of Ankylosing Spondylitis. <i>PLoS ONE</i> , 2016, 11, e0158905.	2.5	15
63	A high density SNP genotyping approach within the 19q13 chromosome region identifies an association of a CNOT3 polymorphism with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 714-717.	0.9	14
64	Erosive discovertebral lesion (Andersson lesion) as the first sign of disease in axial psoriatic arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2013, 42, 220-225.	1.1	14
65	Standards of care and quality indicators for multidisciplinary care models for psoriatic arthritis in Spain. <i>Rheumatology International</i> , 2018, 38, 1115-1124.	3.0	14
66	Recomendaciones para la detección, investigación y derivación del dolor lumbar inflamatorio en Atención Primaria. <i>Reumatología Clínica</i> , 2015, 11, 90-98.	0.5	13
67	Performance of Two Screening Questionnaires for Inflammatory Arthritis in Patients with Inflammatory Bowel Disease. <i>BioMed Research International</i> , 2018, 2018, 1-5.	1.9	13
68	Cardiovascular risk factors influence response to biological therapies in psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 327-329.	1.2	12
69	NFKBIZ in Psoriasis: Assessing the association with gene polymorphisms and report of a new transcript variant. <i>Human Immunology</i> , 2017, 78, 435-440.	2.4	12
70	Minimal Disease Activity and Patient-Acceptable Symptom State in Psoriatic Arthritis. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 381-384.	0.9	12
71	Norma de calidad para el manejo del paciente con artritis psoriásica: proyecto QUANTUM. <i>Reumatología Clínica</i> , 2020, 16, 203-215.	0.5	12
72	Association of IL1 $\beta$ (-511 A/C) and IL6 (-174 G > C) polymorphisms with higher disease activity and clinical pattern of psoriatic arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 1789-1794.	2.2	11

#	ARTICLE	IF	CITATIONS
73	Expert Consensus on a Set of Outcomes to Assess the Effectiveness of Biologic Treatment in Psoriatic Arthritis: The MERECES Study. <i>Journal of Rheumatology</i> , 2020, 47, 1637-1643.	2.0	11
74	Genetic Variants of the NF- $\kappa$ B Pathway: Unraveling the Genetic Architecture of Psoriatic Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13004.	4.1	11
75	HLA-DR17 is associated with enthesitis in psoriatic arthritis. <i>Joint Bone Spine</i> , 2011, 78, 428-429.	1.6	10
76	Hypertension is associated with increased age at the onset of psoriasis and a higher body mass index in psoriatic disease. <i>Clinical Rheumatology</i> , 2019, 38, 2063-2068.	2.2	10
77	Minimal disease activity (MDA) in patients with recent-onset psoriatic arthritis: predictive model based on machine learning. <i>Arthritis Research and Therapy</i> , 2022, 24, .	3.5	10
78	Multiple painful bone cysts in a young man.. <i>Annals of the Rheumatic Diseases</i> , 1996, 55, 346-349.	0.9	9
79	<i>PDE3A-SLCO1C1</i> locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis. <i>Pharmacogenomics</i> , 2014, 15, 1763-1769.	1.3	9
80	Multidisciplinary Care Models for Patients With Psoriatic Arthritis. <i>Reumatolog�a Cl�nica (English)</i> Tj ETQq0 0 0 rgBT/Overlogk 10 Tf 50	0.3	9
81	Polyarticular evolution and late�onset psoriasis may be associated with cardiovascular disease in psoriatic arthritis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 269-274.	1.9	9
82	Remission and stringent treatment goals in psoriatic arthritis: Doctors�™ opinion is not enough. <i>Joint Bone Spine</i> , 2019, 86, 269-270.	1.6	9
83	Definition of Remission and Disease Activity Assessment in Psoriatic Arthritis: Evidence and Expert-Based Recommendations. <i>Reumatolog�a Cl�nica</i> , 2021, 17, 343-350.	0.5	9
84	Consensus statement of the Spanish Society of Rheumatology on the management of biologic therapies in psoriatic arthritis. <i>Reumatolog�a Cl�nica (English Edition)</i> , 2011, 7, 179-188.	0.3	8
85	Stratification by age of onset with 30 years as age limit is an effective means of identifying PSORS1-associated psoriasis in patients with psoriatic arthritis. <i>Joint Bone Spine</i> , 2011, 78, 581-583.	1.6	8
86	Psoriasis and psoriasiform lesions induced by TNF� antagonists: the experience of a tertiary care hospital from northern Spain. <i>Rheumatology International</i> , 2012, 32, 3779-3783.	3.0	8
87	Multidisciplinary care for psoriatic disease. <i>Rheumatology</i> , 2017, 56, kew485.	1.9	8
88	Impact of cardiovascular risk factors on the achievement of therapeutic goals in psoriatic arthritis: is there any association?. <i>Clinical Rheumatology</i> , 2018, 37, 661-666.	2.2	8
89	Enthesitis and joint erosions are disease traits associated with cardiovascular risk in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2020, 39, 2973-2979.	2.2	8
90	Spectrum of psoriatic spondyloarthritis in a cohort of 100 Spanish patients. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 857-858.	0.9	7

#	ARTICLE	IF	CITATIONS
91	Different Clinical Expression of Patients With Ankylosing Spondylitis According to Gender in Relation to Time Since Onset of Disease. Data From REGISPONER. <i>Reumatología Clínica (English Edition)</i> , 2013, 9, 221-225.	0.3	7
92	Gene Variant in the NF- $\kappa$ B Pathway Inhibitor <i>NFKBIA</i> Distinguishes Patients with Psoriatic Arthritis within the Spectrum of Psoriatic Disease. <i>BioMed Research International</i> , 2019, 2019, 1-6.	1.9	7
93	Registro Español de Artritis Psoriásica de Reciente Comienzo (estudio REAPSER). Objetivos y metodología. <i>Reumatología Clínica</i> , 2019, 15, 252-257.	0.5	7
94	Construct Validity of the Routine Assessment of Patient Index Data 3 (RAPID3) in the Evaluation of Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2022, 49, 36-43.	2.0	7
95	C4 deficiency state in antiphospholipid antibody-related recurrent preeclampsia evolving into systemic lupus erythematosus. <i>Rheumatology International</i> , 2002, 22, 126-128.	3.0	6
96	Recommendations of the Spanish Society of Rheumatology on Treatment and Use of Systemic Biological and Non-biological Therapies in Psoriatic Arthritis. <i>Reumatología Clínica (English Edition)</i> , 2018, 14, 254-268.	0.3	6
97	Ustekinumab in psoriatic arthritis: need for studies from real-world evidence. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 931-935.	3.1	6
98	Treatment Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. <i>Arthritis Care and Research</i> , 2020, 72, 814-821.	3.4	6
99	Improving the standard of care for patients with spondyloarthritis-related immune inflammatory conditions: results of a Delphi study and proposal for early detection. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232090429.	2.5	6
100	Evaluating standards of care in psoriatic arthritis of the QUANTUM project (qualitative initiative to) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i> 1817-1823.	3.0	6
101	Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study. <i>Arthritis Research and Therapy</i> , 2020, 22, 82.	3.5	6
102	Mismatch between the impact of disease perceived by patients and the state of clinical remission assessed by physicians in psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 333-336.	0.8	6
103	Ankylosing Spondylitis without Axial Progression: Analysis of Associated Factors. <i>Journal of Rheumatology</i> , 2014, 41, 2409-2412.	2.0	5
104	Recommendations for the Detection, Study and Referral of Inflammatory Low-back Pain in Primary Care. <i>Reumatología Clínica (English Edition)</i> , 2015, 11, 90-98.	0.3	5
105	Recomendaciones sobre el uso de metotrexato en pacientes con artritis psoriásica. <i>Reumatología Clínica</i> , 2018, 14, 183-190.	0.5	5
106	Estado actual de la atención multidisciplinar para pacientes con artritis psoriásica en España: proyecto NEXUS 2.0. <i>Reumatología Clínica</i> , 2020, 16, 24-31.	0.5	5
107	Enfermedad de Pyle: un modelo humano de homeostasis corticotrabecular diferenciada. <i>Reumatología Clínica</i> , 2020, 16, 56-58.	0.5	5
108	Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study. <i>European Journal of Clinical Nutrition</i> , 2021, 75, 1368-1382.	2.9	5

#	ARTICLE	IF	CITATIONS
109	Potential Differences in the Cardiometabolic Risk Profile of Patients with Psoriatic Disease according to Their HLA-C Status. <i>BioMed Research International</i> , 2022, 2022, 1-7.	1.9	5
110	Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning. <i>Frontiers in Medicine</i> , 2022, 9, 891863.	2.6	5
111	The Region Centromeric to HLA-C Is a Key Region for Understanding the Phenotypic Variability of Psoriatic Arthritis. <i>ISRN Dermatology</i> , 2014, 2014, 1-5.	1.9	4
112	Inflammation-fatigue in spondyloarthritis: a clear link in axial spondyloarthritis but less so in psoriatic arthritis. <i>Rheumatology</i> , 2021, 60, 3023-3025.	1.9	4
113	Management of particular clinical situations in psoriatic arthritis: an expert's recommendation document based on systematic literature review and extended Delphi process. <i>Rheumatology International</i> , 2021, 41, 1549-1565.	3.0	4
114	The ASAS Health Index: A New Era for Health Impact Assessment in Spondyloarthritis. <i>Journal of Rheumatology</i> , 2022, 49, 8-15.	2.0	4
115	PsAID High-impact Disease in Psoriatic Arthritis: A Component Weighting Analysis of the Assessment of SpondyloArthritis international Society Health Index. <i>Journal of Rheumatology</i> , 2021, 48, 1886-1888.	2.0	4
116	Cardiometabolic comorbidity in the selection of treatment in spondyloarthritis: one step closer to truly personalized medicine?. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1539-1541.	3.1	4
117	Analysis by Age Group of Disease Outcomes in Patients with Psoriatic Arthritis: A Cross-Sectional Multicentre Study. <i>Drugs and Aging</i> , 2020, 37, 99-104.	2.7	3
118	Family history of disease in spondyloarthritis: a key issue for disease prognosis. <i>Rheumatology</i> , 2020, 59, 2657-2658.	1.9	3
119	Analysis of the HAQ-DI components in psoriatic arthritis patients with and without low disease impact. <i>Rheumatology</i> , 2020, 59, 3569-3570.	1.9	3
120	Hyperlipidaemia in psoriatic disease: higher prevalence in psoriatic arthritis and inverse association with systemic therapy. <i>Rheumatology</i> , 2021, 60, 3949-3951.	1.9	3
121	A polyarticular onset and diabetes could be the main predictors of cardiovascular events in psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 276-81.	0.8	3
122	Sexual disinterest among spondyloarthritis patients. Comparison between psoriatic arthritis and axial spondyloarthritis using a sexuality-specific question from the ASAS Health Index. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 922-923.	0.8	3
123	May Some Cases of Intermittent Hydrarthrosis Represent an Atypical Form of Calcium Pyrophosphate Dihydrate Crystal Deposition Disease? Usefulness of Mutational Analysis of the MEFV Gene. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 37, 269-270.	3.4	2
124	Determinants of psoriatic arthritis in patients with psoriasis. <i>Expert Review of Dermatology</i> , 2010, 5, 67-77.	0.3	2
125	Quality standard for the management of patients with psoriatic arthritis: QUANTUM project. <i>Reumatología Clínica (English Edition)</i> , 2020, 16, 203-215.	0.3	2
126	Structural damage is not a major driver of disease impact in patients with long-standing psoriatic arthritis undergoing systemic therapy. <i>Joint Bone Spine</i> , 2021, 88, 105116.	1.6	2



#	ARTICLE	IF	CITATIONS
127	Propuesta de norma de certificación de calidad «SPACE» para unidades de tratamiento de pacientes con espondiloartritis axial. Reumatología Clínica, 2021, , .	0.5	2
128	Disease Activity in Psoriatic Arthritis Index and Psoriatic Arthritis Impact of Disease Questionnaire: correlation and sensitivity to change in a real clinical setting. Clinical and Experimental Rheumatology, 2020, 38, 973-977.	0.8	2
129	Confounders contributing to explain the association between sex and disease impact in patients with recent-onset psoriatic arthritis. Clinical and Experimental Rheumatology, 0, , .	0.8	2
130	Recommendations for the Use of Methotrexate in Psoriatic Arthritis. Reumatología Clínica (English) Tj ETQq0 0 0 ggBT /Overlock 10 Tf 0.3	0.3	1
131	FRI0450â€¦PROBABILITY OF ACHIEVING LOW DISEASE ACTIVITY OR REMISSION IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH APREMILAST. , 2019, , .		1
132	Ultrasound subclinical musculoskeletal findings in inflammatory bowel disease: diagnostic value of positive Doppler signal. Rheumatology, 2020, 59, 3571-3572.	1.9	1
133	ASAS Health Index as an Addition to Routine Clinical Practice. Journal of Rheumatology, 2021, 48, 787-787.	2.0	1
134	Female psoriatic arthritis: not just a matter of greater disease activity but of greater routine life impact. Clinical Rheumatology, 2021, 40, 1663-1665.	2.2	1
135	Differentiating facets of quality of life between spondyloarthritis phenotypes: added value of the ASAS health index. Rheumatology, 2021, , .	1.9	1
136	Manifestaciones atípicas de la enfermedad de Whipple. Anales De Medicina Interna, 2001, 18, .	0.1	1
137	Distribution of the components of the MDA response among patients with psoriatic arthritis with and without an acceptable symptomatic state. Clinical and Experimental Rheumatology, 2020, 38, 575-576.	0.8	1
138	Comorbilidades en las espondiloartropatías. Seminarios De La Fundacióñ Española De Reumatología, 2010, 11, 89-93.	0.1	0
139	Ustekinumab en la artritis psoriásica y la enfermedad de Crohn. Actas Dermo-sifilográficas, 2012, 103, 65-72.	0.4	0
140	SAT0311â€¦Men and women with psoriatic arthritis express a different genetic profile within the major histocompatibility complex region. Annals of the Rheumatic Diseases, 2013, 71, 577.2-577.	0.9	0
141	AB0588â€¦Prevalence of conventional cardiovascular risk factors in patients with psoriasis alone and in patients with psoriatic arthritis. Annals of the Rheumatic Diseases, 2013, 72, A969.3-A970.	0.9	0
142	FRI0556â€¦Development of standards of care in spondyloarthritis. Annals of the Rheumatic Diseases, 2013, 72, A563.3-A563.	0.9	0
143	AB0764â€¦An Onset of Psoriasis after 40 Years and A Low Education Level May PREDICT the Development of Diabetes Mellitus in Psoriatic Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 1057.2-1057.	0.9	0
144	SAT0410â€¦Determinants of Hypertension in Patients with Psoriatic Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 743.2-743.	0.9	0

#	ARTICLE	IF	CITATIONS
145	AB0736â€¦Strategy for the Early Detection and Referral of Patients with Suspected Spondyloarthritis: Table 1. Annals of the Rheumatic Diseases, 2014, 73, 1046.3-1047.	0.9	0
146	AB0823â€¦Age at Disease Onset Helps to Further Characterize the Disease Phenotype in Psoriatic Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1175.2-1175.	0.9	0
147	AB0824â€¦Predictors of Cerebrovascular Disease Among Psoriatic Arthritis Patients. Annals of the Rheumatic Diseases, 2015, 74, 1176.1-1176.	0.9	0
148	AB1133â€¦Epidemiological Comparative Analysis in a Large Cohort of Psoriatic Arthritis Patients: Results of the Spanish IMID Consortium. Annals of the Rheumatic Diseases, 2015, 74, 1280.3-1280.	0.9	0
149	RÃ©mission et objectifs thÃ©rapeutiques rigoureux dans le rhumatisme psoriasiqueÃ: le point de vue des mÃ©decins ne suffit pas. Revue Du Rhumatisme (Edition Francaise), 2019, 86, 641-642.	0.0	0
150	Current status of multidisciplinary care in psoriatic arthritis in Spain: NEXUS 2.0 project. ReumatologÃa ClÃnica (English Edition), 2020, 16, 24-31.	0.3	0
151	A comparison of disease impact according to the cardiometabolic risk profile in psoriatic arthritis. Archives of Medical Science, 2021, 17, 557-560.	0.9	0
152	Definition of Remission and Disease Activity Assessment in Psoriatic Arthritis: Evidence and Expert-Based Recommendations. ReumatologÃa ClÃnica (English Edition), 2021, 17, 343-350.	0.3	0
153	PSORIASIS 696.1. , 2008, , 157-158.		0
154	Psoriatic Arthritis: A Current Vision. , 2019, , 105-105.		0
155	Quality certification standard proposal â€œSPACEâ€¢for axial spondyloarthritis treatment units. ReumatologÃa ClÃnica (English Edition), 2021, , .	0.3	0
156	Disease impact in axial spondyloarthritis: Divergent roles between family history of disease and HLA-B27?. ReumatologÃa ClÃnica, 2021, , .	0.5	0
157	Good clinimetric alignment between remission and a low impact of disease in patients with axial psoriatic arthritis. Clinical and Experimental Rheumatology, 2020, 38, 136-139.	0.8	0
158	Active Disease in Psoriatic Arthritis: An Assessment of Spondyloarthritis International Society Health Index (ASAS-HI)â€¢based Analysis. Journal of Rheumatology, 0, , jrheum.210887.	2.0	0